循环的无细胞DNA作为帕金森病的预测因素
Ketan S Patil1, Johannes Lange2, Adam Constantine3
1Department of Biological Sciences, St. John's University, New York, NY, USA.
Parkinsonism & related disorders
|June 15, 2025
概括
血清无细胞DNA (cfDNA) 显示为帕金森病 (PD) 诊断的生物标志物具有前途. 这项研究确定了特定的cfDNA片段,可以准确地预测新患者和治疗患者的PD.
科学领域:
- 生物标志物 生物标志物
- 基因组学就是基因组学.
- 神经退行性疾病 神经退行性疾病
背景情况:
- 准确的帕金森病 (PD) 诊断是具有挑战性的,需要新的分子生物标志物.
- 循环无细胞DNA (cfDNA) 是一种潜在的疾病检测途径.
研究的目的:
- 为了识别,验证和验证血清cfDNAs作为PD的诊断预测因素.
- 评估cfDNA在未使用药物和暴露药物的PD患者队列中的实用性.
主要方法:
- 下一代测序和复制数分析从前未使用过药物的PD和对照血清样本中的cfDNA.
- 定量实时聚合酶连锁反应 (qRT-PCR) 用于在独立队列中进行确认和验证.
- 包括ROC曲线和AUC值在内的统计分析,以评估诊断准确性.
主要成果:
- 确定了16个潜在的cfDNA区域,PD和对照组之间的水平差异很大.
- 13个cfDNA片段证实在以前没有服用过药物的PD患者中含量明显更高.
- 七个cfDNA片段的AUC达到0.9-0.93;在暴露于药物的PD患者中验证的三个片段的AUC为0.90-0.93.
结论:
- 血清cfDNA分子显示出作为PD预测因子的巨大潜力.
- 这些cfDNA生物标志物可以补充帕金森病的现有诊断方法.
相关概念视频
EPS and iPS Cells in Disease Research
2.9K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.9K
Neural Regulation
40.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.4K
Parkinson's Disease: Overview
723
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
723


